Alnylam Pharmaceuticals (ALNY) EBITDA Margin (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) reported EBITDA Margin of 17.24% for Q1 2026, up 8807.0% on a YoY basis from 0.19% in Q1 2025, and up 67.02% quarter-over-quarter from 10.32% in Q4 2025.
Alnylam Pharmaceuticals (ALNY) EBITDA Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals has reported EBITDA Margin for 18 years, with the latest figure at 17.24% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 8807.0% year-over-year to 17.24%; the trailing twelve-month figure through Mar 2026 stood at 12.01% (up 2552.0% YoY), and the FY2025 full-year result was 8.84%, up 2170.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 17.24%, up from 10.32% in the prior quarter.
- The five-year high for EBITDA Margin was 20.76% in Q3 2025, with the low at 154.17% in Q3 2022.
- Historically, EBITDA Margin has averaged 40.49% across 5 years, with a median of 20.31% in 2024.
- Annual changes were most pronounced in 2023 — EBITDA Margin jumped 17449 bps — and 2025, when it tumbled 5676 bps.
- Alnylam Pharmaceuticals' EBITDA Margin stood at 62.19% in 2022, then soared by 53 bps to 29.32% in 2023, then jumped by 46 bps to 15.76% in 2024, then surged by 166 bps to 10.32% in 2025, then soared by 67 bps to 17.24% in 2026.
- The last three EBITDA Margin figures came in at 17.24% (Q1 2026), 10.32% (Q4 2025), and 20.76% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.04 Bn | 34.03 Bn | 959.66 Mn | 17.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.24% |
| Dec 31, 2025 | 10.32% |
| Sep 30, 2025 | 20.76% |
| Jun 30, 2025 | -7.59% |
| Mar 31, 2025 | -70.83% |
| Dec 31, 2024 | -15.76% |
| Sep 30, 2024 | -20.31% |
| Jun 30, 2024 | -3.72% |
| Mar 31, 2024 | -14.07% |
| Dec 31, 2023 | -29.32% |
| Sep 30, 2023 | 20.32% |
| Jun 30, 2023 | -85.95% |
| Mar 31, 2023 | -52.80% |
| Dec 31, 2022 | -62.19% |
| Sep 30, 2022 | -154.17% |
| Jun 30, 2022 | -125.24% |
| Mar 31, 2022 | -114.95% |
| Dec 31, 2021 | -99.60% |
| Sep 30, 2021 | -108.01% |
| Jun 30, 2021 | -85.66% |